Royal Bank Of Canada Forecasts Strong Price Appreciation for Ralliant (NYSE:RAL) Stock

Posted by Geri Gentry on Jul 31st, 2026

Ralliant (NYSE:RAL – Get Free Report) had its price objective boosted by research analysts at Royal Bank Of Canada from $71.00 to $73.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “sector perform” rating on the stock. Royal Bank Of Canada’s price target would indicate a potential upside of 9.53% from the company’s previous close.

A number of other research firms also recently weighed in on RAL. Oppenheimer raised their target price on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, May 13th. BMO Capital Markets started coverage on shares of Ralliant in a research report on Monday, July 20th. They set a “market perform” rating and a $78.00 price target on the stock. Truist Financial restated a “buy” rating and set a $82.00 price objective (up from $68.00) on shares of Ralliant in a research note on Friday. Citigroup raised their price objective on Ralliant from $70.00 to $81.00 and gave the company a “buy” rating in a report on Monday, July 13th. Finally, Evercore initiated coverage on Ralliant in a research report on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $75.60.

Check Out Our Latest Research Report on RAL

Ralliant Stock Down 0.5%

Shares of RAL traded down $0.35 during mid-day trading on Friday, hitting $66.65. 1,223,872 shares of the company’s stock were exchanged, compared to its average volume of 1,711,941. The company has a market cap of $7.46 billion and a PE ratio of -6.09. Ralliant has a 52 week low of $37.27 and a 52 week high of $75.41. The company has a 50-day simple moving average of $67.12 and a 200 day simple moving average of $54.26. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 1.05.

Ralliant (NYSE:RAL – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. The company had revenue of $567.80 million for the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, research analysts forecast that Ralliant will post 2.64 earnings per share for the current fiscal year.

Institutional Trading of Ralliant

A number of large investors have recently added to or reduced their stakes in the company. Phocas Financial Corp. lifted its stake in Ralliant by 81.2% in the 4th quarter. Phocas Financial Corp. now owns 157,116 shares of the company’s stock valued at $7,999,000 after purchasing an additional 70,403 shares during the last quarter. Teacher Retirement System of Texas increased its position in Ralliant by 6.9% during the fourth quarter. Teacher Retirement System of Texas now owns 570,878 shares of the company’s stock worth $29,063,000 after buying an additional 36,800 shares during the last quarter. Alpha Omega Wealth Management LLC increased its position in Ralliant by 615.8% during the fourth quarter. Alpha Omega Wealth Management LLC now owns 40,291 shares of the company’s stock worth $2,051,000 after buying an additional 34,662 shares during the last quarter. Rokos Capital Management LLP acquired a new position in Ralliant during the first quarter worth approximately $42,022,000. Finally, Irenic Capital Management LP raised its stake in Ralliant by 424.1% in the first quarter. Irenic Capital Management LP now owns 1,740,218 shares of the company’s stock valued at $72,376,000 after buying an additional 1,408,176 shares during the period.

Ralliant News Roundup

Here are the key news stories impacting Ralliant this week:

Positive Sentiment: Truist raised its price target: Truist Financial reaffirmed its “buy” rating and increased its target to $82 from $68, implying substantial upside from the current trading level. Benzinga
Positive Sentiment: Second-quarter earnings beat expectations: Ralliant reported adjusted EPS of $0.68, ahead of the $0.63 consensus estimate and slightly above $0.67 a year earlier. Revenue reached approximately $568 million, up 13% year over year on both a reported and organic basis. Net earnings were $57 million, while adjusted net earnings were $76 million. Ralliant Reports Second Quarter 2026 Results and Raises Full Year Guidance
Positive Sentiment: Management raised its outlook: Ralliant’s third-quarter guidance calls for adjusted EPS of $0.72–$0.78 and revenue of $570–$590 million, both above consensus estimates. Full-year adjusted EPS guidance increased to $2.76–$2.90 from an analyst estimate of $2.65, with projected revenue of roughly $2.25–$2.30 billion. Ralliant 2026 Revenue Forecast and Productivity Program
Positive Sentiment: Cost savings could support future margins: The company’s enterprise productivity program targets $50 million–$60 million in annualized savings by 2028, adding a potential longer-term earnings catalyst.
Neutral Sentiment: Trading in RAL was temporarily paused on July 30 under a limit-up/limit-down (LULD) volatility halt. The reports do not identify a company-specific negative catalyst behind the subsequent weakness.

About Ralliant

(Get Free Report)

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.